4D Molecular Therapeutics Azioni (NASDAQ: FDMT)

Ultime notizie per 4D Molecular Therapeutics (NASDAQ:FDMT) Azioni

4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics Inc

U.S. stocks could open on a tentative note on Tuesday after the <a href="https://www.benzinga.com/news/earnings/24/11/41696201/market-volatility-soars-ahead-of-elections-tech-earnings-mixed-strikes-and-hurricanes-knock-employm">averages registered a mixed October</a>. Futures of all three major indices were slightly up on Tuesday, pointing to a cautious sentiment on Wall Street.
While the S&amp;P 500 and Dow Jones snapped their six-week winning streak, the Nasdaq Composite chalked its seventh straight week of gains to round off a volatile October.
America goes to polls on Tuesday to elect its 47th president, and data so far suggests that it will be a neck-to-neck race between Democratic candidate&nbsp;Kamala Harris&nbsp;and Republican nominee&nbsp;Donald Trump.
Another factor playing on investors' minds will be the Federal Open Market Committee's (FOMC) rate decision – the prevailing sentiment is that the Fed will deliver a 25-basis point cut.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.27%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.16%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.12%</td>
</tr>
<tr>
<td>R2K</td>
<td>0.05%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Tuesday,&nbsp;the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.16% to $570.71 and the&nbsp;Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged up by 0.25% to $487.24, according to&nbsp;<a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Cues From Last Session:
The Dow Jones tumbled over 250 points on Monday, closing the day down by 0.61%. The other two averages also declined amid declining investor sentiment and rising fear in the market.
Oil prices continued to rebound after tanking the week before, amid delays in production output increase by the Organization of the Petroleum Exporting Countries, or OPEC.
Treasury yields continued to rise, signaling concerns that regardless of who wins the elections, the next administration might struggle with fiscal discipline. This sentiment was further exacerbated by the International Monetary Fund's warnings on the long-term trajectory <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41495286/deficit-strain-in-washington-will-get-worse-imf-warns-national-debt-projections-rev" target="_blank" rel="noreferrer noopener">of the U.S. national debt</a>.
On the economic data front, U.S. factory orders declined by 0.5% from the previous month to $584.2 billion in September compared to a revised 0.8% fall in August.
Most sectors on the S&amp;P 500 closed on a negative note, with utilities, communication services, and financials stocks recording the biggest losses on Monday.
However, energy and real estate stocks bucked the overall market trend, closing the session higher.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.33%</td>
<td>18,179.98</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.28%</td>
<td>5,712.62</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.61%</td>
<td>41,794.60</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.40%</td>
<td>2,219.03</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
Ryan Detrick, chief market strategist at Carson Group, underscored that stocks perform well on election day, which could assuage investor concerns amid rising volatility.
"What really stands out is how well stocks have done after the 10 most recent elections. Higher a year later 9 times and up 15.2% on avg (median of 17.2%)," he said.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s how stocks have done after the past 24 elections. What really stands out is how well stocks have done after the 10 most recent elections. Higher a year later 9 times and up 15.2% on avg (median of 17.2%). <a href="https://t.co/ztim9o3RxP">pic.twitter.com/ztim9o3RxP</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1853476226741989530?ref_src=twsrc%5Etfw">November 4, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Echoing Detrick's sentiment, WisdomTree and Wharton School economist&nbsp;Jeremy Siegel said the equity bull run could continue.
"In the near term, stock markets seem poised for further gains, bolstered by resilient earnings and steady economic fundamentals, while bond markets will likely grapple with higher yields and volatility ahead," he said.
"The bull market in stocks looks set to continue, while bonds face a rougher road."
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Tuesday's economic calendar is fairly light.
<ul>
<li>On Tuesday, U.S. trade deficit data will be released at 8:30 a.m. ET.</li>
<li>ISM services data will be released at 10 a.m. ET.</li>
<li>API weekly crude oil stock data will be released at 4:30 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares soared 5.6% on election eve.</li>
<li>Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares surged 13% in premarket trading after the company delivered strong performance and raised guidance.</li>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) shares rose nearly 2% after striking machinists ratified a new deal late Monday, ending a seven-week-long strike.</li>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) stock fell over 5% after the company's soft guidance, despite beating expectations in the September quarter.</li>
<li>Investors are awaiting earnings results from Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>), Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) and Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures surged in the early New York session, rising by 0.4% after OPEC announced a delay in increasing production.
The 10-year Treasury note yield surged to 4.311%.
Major Asian markets ended in the green on Tuesday, and European stocks showed strength as well in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases">Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases</a></li>
</ul>
Photo courtesy: Wikimedia

Earnings

Equities

News

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

NXPI

PLTR

US Stocks Set For Cautious Start As Investors Brace For Volatility On Election Day: Expert Points To 'Pretty Well Overall' Historical Performance

WIIM

WYNN

Wynn Resorts shares are trading lower after the company reported worse-than-expected Q3 EPS and revenues.

AZPN

Emerson Proposes To Acquire Remaining Outstanding Shares Of AspenTech For $240 Per Share In Cash

Fiscal 2025 Guidance
Certain statements in this release, including without limitation, those in this section, are forward-looking statements. For additional information regarding the use and limitations of such statements, refer to "Cautionary Note Regarding Forward-Looking Statements" below.
Based on results for the first quarter of fiscal 2025 and its current outlook for the remainder of the fiscal year, the company is reaffirming the following:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Guidance Metric</td>
<td colspan="1" rowspan="1">Fiscal 2025 Guidance Range [1] [2] (as of November 5, 2024)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Net Revenue:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Supply Chain Services</td>
<td colspan="1" rowspan="1">$560 million to $610 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Performance Services Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$370 million to $410 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Net Revenue Excluding Contigo Health</td>
<td colspan="1" rowspan="1">$930 million to $1.02 billion</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$235 million to $255 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">$1.16 to $1.28</td>
</tr>
<tr>
<td colspan="2" rowspan="1">
Fiscal 2025 guidance is based on the realization of the following key assumptions:
<ul>
<li>Net administrative fees revenue of $495 million to $525 million, which includes $60 million to $75 million in revenue related to non-healthcare member purchasing</li>
<li>Supply Chain Services segment software licenses, other services and support revenue of $65 million to $85 million</li>
<li>Capital expenditures of $90 million to $100 million</li>
<li>Effective income tax rate in the range of 25% to 27%</li>
<li>Cash income tax rate of less than 5%</li>
<li>Free cash flow of 45% to 55% of adjusted EBITDA</li>
</ul>
</td>
</tr>
</tbody>
</table>
</figure>

Guidance

PINC

Premier Expects FY25 Net Revenue Of $930M-$1.02B Vs $977.19M Est, Adj EPS Of $1.16-$1.28 Vs $1.21 Est

Emerson Commences Review Of Strategic Options For Safety & Productivity Segment

JMP Securities analyst Jordan Bender upgrades Century Casinos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTY#NASDAQ">CNTY</a>) from Market Perform to Market Outperform and announces $5 price target.

Upgrades

Price Target

Analyst Ratings

CNTY

JMP Securities Upgrades Century Casinos to Market Outperform, Announces $5 Price Target

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 33.33 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $15.853 million which beat the analyst consensus estimate of $15.850 million by 0.02 percent. This is a 2.76 percent decrease over sales of $16.303 million the same period last year.

Earnings Beats

Earnings Misses

SOPH

Sophia Genetics Q3 2024 GAAP EPS $(0.28) Misses $(0.22) Estimate, Sales $15.853M Beat $15.850M Estimate

Celanese shares are trading lower after the company reported worse-than-expected Q3 financial results and announced it intends to temporarily reduce its quarterly dividend.

Truist Securities analyst Jamie Cook downgrades Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and lowers the price target from $46 to $43.

Downgrades

CGNX

Truist Securities Downgrades Cognex to Hold, Lowers Price Target to $43

Buybacks

Emerson Reveals Increased Return of Capital To Shareholders With Plans To Repurchase Approximately $2B Of Shares In FY25; Expecting $1B In Fiscal Q1

Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) released its Q3 earnings on Thursday, October 24, 2024 at 04:05 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Boyd Gaming beat estimated earnings by 10.0%, reporting an EPS of $1.52 versus an estimate of $1.38.
Revenue was up $58.08 million from the same period last year.
<h3>Analysis of Past Earnings</h3>
The company beat on EPS by $0.09 in the last quarter, resulting in a 4.0% increase share price change the following day.
Here's a look at Boyd Gaming's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.38</td>
<td>1.49</td>
<td>1.57</td>
<td>1.47</td>
<td>1.47</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.58</td>
<td>1.51</td>
<td>1.66</td>
<td>1.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>912.95M</td>
<td>909.06M</td>
<td>958.74M</td>
<td>930.47M</td>
<td>879.82M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>961.25M</td>
<td>967.51M</td>
<td>960.52M</td>
<td>954.41M</td>
<td>903.16M</td>
</tr>
</tbody>
</table>

<h3>Competitors' Recent Earnings Updates</h3>
It's important to consider Boyd Gaming's numbers in relation to how its competitors, like PENN Entertainment, Golden Entertainment, and Inspired Entertainment, have been performing.
<ul>
<li>PENN Entertainment announced strong earnings on August 08, 2024, surpassing market expectations. Despite an estimated EPS of $-0.26, PENN Entertainment's actual EPS was $-0.18, reflecting a 30.77% increase.</li>
<li>Despite market projections of an EPS of $0.21, Golden Entertainment's earnings on August 08, 2024 fell short with an actual EPS of $0.02, representing a -90.48% decrease from expectations.</li>
<li>The latest earnings announcement from Inspired Entertainment on August 08, 2024 exceeded expectations, with an actual EPS of $0.2 compared to the market's estimate of $0.1, resulting in a 100.0% increase.</li>
</ul>
<h3>Insights into Competitors' Quarterly Earnings and Stock Performance</h3>
The analysis presented here offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>October 24, 2024</td>
<td style="text-align: right;">1.38</td>
<td style="text-align: right;">1.52</td>
<td>10.14%</td>
<td>$64.31</td>
<td>$69.96</td>
<td>8.79%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.26</td>
<td style="text-align: right;">-0.18</td>
<td>30.77%</td>
<td>$18.72</td>
<td>$18.83</td>
<td>0.59%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.21</td>
<td style="text-align: right;">0.02</td>
<td>-90.48%</td>
<td>$28.12</td>
<td>$27.42</td>
<td>-2.49%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.10</td>
<td style="text-align: right;">0.20</td>
<td>100.0%</td>
<td>$8.48</td>
<td>$8.39</td>
<td>-1.06%</td>
</tr>
</tbody>
</table>

<h3>Analyzing Peer Revenue Discrepancy: Estimated vs. Announced</h3>
Here's a comparison table presenting estimated and announced revenue figures for Boyd Gaming's peers. This comparison offers insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boyd Gaming</td>
<td>912.95M</td>
<td>961.25M</td>
<td>5.29%</td>
</tr>
<tr>
<td>PENN Entertainment</td>
<td>1.66B</td>
<td>1.66B</td>
<td>0.18%</td>
</tr>
<tr>
<td>Golden Entertainment</td>
<td>174.60M</td>
<td>167.33M</td>
<td>-4.16%</td>
</tr>
<tr>
<td>Inspired Entertainment</td>
<td>74.41M</td>
<td>75.60M</td>
<td>1.6%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Boyd Gaming <a href="https://www.benzinga.com/quote/BYD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Boyd Gaming Earnings Review: Q3 Summary

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent.

MITT

AG Mortgage Investment Q3 2024 Adj EPS $0.17 Beats $0.16 Estimate

NXP Semiconductors shares are trading lower after the company issued soft guidance.

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 4D Molecular Therapeutics (FDMT – Research Report) a...

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 4D Molecular Therapeutics (FDMT – Research Report) and Progyny (P...

Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Progyny (PGNY)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IGM Biosciences (IGMS – Research Report) and 4D Mole...

Analysts Are Bullish on These Healthcare Stocks: IGM Biosciences (IGMS), 4D Molecular Therapeutics (FDMT)

Janus Henderson Global Life Sciences Fund Q2 2024 Commentary

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary

4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Warning: FDMT is at high risk of performing badly

ABBV

ADVM

AMGN

ASND

AVDL

AZNCF

BHVN

ETNB

FDMT

GMED

IGMS

INSM

MSCLF

NONOF

NVSEF

PGNY

REGN

RGNX

SNYNF

SRPT

UTHR

VRTX

Press Releases

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

4DMT Announces Presentations at Upcoming Retina Conferences

Small Cap

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

Health Care

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

Comments

4D Molecular Therapeutics

Notizie

Ultime notizie per 4D Molecular Therapeutics (NASDAQ:FDMT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO